Blog
RSS FeedPosted by Michael Wonder on 05 Mar 2025
Sparsentan for the treatment of patients with primary IgA nephropathy
4 March 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 05 Mar 2025
Obesity management needs medications on PBS: RACGP
4 March 2025 - The college’s new obesity position statement calls for extra funding to treat the complex condition and for ...
Posted by Michael Wonder on 03 Mar 2025
Canada’s Drug Agency publishes new guidance for rare disease registries in Canada
28 February 2025 - On Rare Disease Day — a global event dedicated to raising awareness for the millions of ...
Posted by Michael Wonder on 03 Mar 2025
Cushing’s disease: drug added to PBS
2 March 2025 - Australians suffering from the debilitating condition Cushing’s disease have scored a huge win after a vital ...
Posted by Michael Wonder on 03 Mar 2025
PHARMAC CE resigns
28 February 2025 - The Board of PHARMAC wishes to announce that its Chief Executive for the last 7 years, ...
Posted by Michael Wonder on 03 Mar 2025
New Zealand Pharmaceutical Schedule - 1 March 2025
1 March 2025 - The March 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 01 Mar 2025
Bimzelx (bimekizumab) negotiations with pCPA concluded successfully following positive CDA and INESSS recommendations for adults with active psoriatic arthritis and adults with active ankylosing spondylitis
28 February 2025 - Positive CDA and INESSS reimbursement recommendations are an important step towards public access to Bimzelx, the first ...
Posted by Michael Wonder on 28 Feb 2025
Government of Canada signs Pharmacare agreement with Manitoba to improve affordable access to medications
27 February 2025 - Additional agreement will improve access and affordability of drugs for rare diseases. ...
Posted by Michael Wonder on 26 Feb 2025
Exagamglogene autotemcel for the treatment of patients with severe sickle cell disease
26 February 2025 - NICE has published final evidence-based recommendations on the use of exagamglogene autotemcel (Casgevy) for the treatment ...
Posted by Michael Wonder on 26 Feb 2025
Osimertinib mesylate for the adjuvant treatment of patients with EGFR mutation positive non-small-cell lung cancer after complete tumour resection (final guidance)
26 February 2025 - NICE has published final evidence-based recommendations on the use of osimertinib mesylate (Tagrisso) for the adjuvant ...
Posted by Michael Wonder on 21 Feb 2025
Green light for groundbreaking personalised cancer therapy that reprogrammes immune system
20 February 2025 - Final guidance published today recommends lisocabtagene maraleucel (Breyanzi; Bristol Myers Squibb) as an option for treating ...
Posted by Michael Wonder on 21 Feb 2025
Harmonising HTA evidence needs and expectations: challenges and opportunities to improve evidence generation, ensure access and affordability
19 February 2025 - Conducting high quality health technology assessments requires high quality evidence. With evolving regulatory standards for faster approval ...
Posted by Michael Wonder on 21 Feb 2025
Use of surrogate endpoints in health technology assessment: a review of selected NICE technology appraisals in oncology
19 February 2025 - Surrogate endpoints, used to substitute for and predict final clinical outcomes, are increasingly being used to support ...
Posted by Michael Wonder on 19 Feb 2025
Selpercatinib for the treatment of patients with advanced RET fusion positive non-small-cell lung cancer
19 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...
Posted by Michael Wonder on 19 Feb 2025
Durvalumab in combination with etoposide phosphate and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small-cell lung cancer
19 February 2025 - NICE has published final evidence-based recommendations on the use of durvalumab (Imfinzi) in combination with etoposide ...